This summer, a new wave of Covid-19 has impacted regions worldwide, including Alaska.
In early 2024, Alaska experienced a significant spike, reaching 746 cases in January. By mid-year, cases began to rise again as a global surge continued. Dr. Joe McLaughlin, the state epidemiologist with the Alaska Department of Health, noted, “The summer Covid-19 surge has affected at least 84 countries.” In July, Alaska saw a peak of 417 cases.
Although the current surge has fewer cases than January’s peak, it is fueled by new virus variants. “We’re seeing what are called flirt variants. The two main ones are kp2 and kp3,” McLaughlin explained. Additionally, kp3.1.1 has emerged as a significant variant, representing a quarter of all cases nationwide.
Summer travel has contributed to the spread. Tourists visiting Alaska and residents returning from vacations have likely brought the virus with them. McLaughlin noted, “These factors have likely contributed to the virus reaching the state.”
Despite increased immunity from past infections, vaccinations remain crucial. They help reduce the risk of severe illness and complications. “Vaccinations are highly effective in preventing hospitalization and death,” McLaughlin said. “They also help prevent long Covid.”
For those infected, treatments are available. While some may only need over-the-counter medications and rest, others, particularly those at higher risk, might benefit from treatments like Paxlovid. This medication is available for individuals aged 12 and older who are at risk of severe disease, including older adults and those with weakened immune systems.
Individuals can choose whether to use masks to protect themselves, but it is recommended to wear one if someone in your household is infected. “People should stay home or avoid work and school until at least 24 hours after their fever resolves without medication,” advised McLaughlin.
Although the virus can be spread for up to five days after symptoms start, the risk decreases after the fever ends.
A new Covid-19 booster vaccine, targeting the latest variants, will be available this fall, according to Dr. McLaughlin.
